利妥昔单抗生物类似药对弥漫大B细胞淋巴瘤总生存的影响:荷兰人群研究
本研究基于荷兰癌症登记处2014—2018年诊断为弥漫大B细胞淋巴瘤且接受至少1周期R-CHOP方案治疗的成人患者,比较利妥昔单抗原研药与生物类似药的总生存。结果显示两组3年总生存率均为73%(P=.855),多因素Cox回归证实无差异,支持在DLBCL治疗中使用利妥昔单抗生物类似药。
要点
- 接受R-CHOP的DLBCL患者中,利妥昔单抗生物类似药组与原研药组3年OS均为73%(P=.855)。
- 多因素Cox回归校正性别、年龄、IPI评分和R-CHOP周期数后,OS仍无差异。
- 生物类似药组接受>6周期R-CHOP的比例较低(24% vs 30%,P=.003),但未影响OS。
核心结论
- 接受R-CHOP治疗的DLBCL患者中,使用利妥昔单抗生物类似药与原研药的3年总生存相似,支持生物类似药在DLBCL治疗管理中的应用。
研究设计与样本
- 基于荷兰癌症登记处的人群研究,纳入2014—2018年诊断、年龄≥18岁、接受至少1周期R-CHOP的DLBCL患者。
- 根据荷兰药品市场中央数据库数据将患者分为利妥昔单抗原研药组和生物类似药组,主要终点为3年总生存。
- 共纳入4429例患者,其中生物类似药组876例,原研药组3553例;截至2018年底,91%的利妥昔单抗采购为生物类似药。
主要发现
- 生物类似药组接受>6周期R-CHOP的患者比例低于原研药组(24% vs 30%,P=.003)。
- 两组3年总生存率均为73%(P=.855)。
- 多因素Cox回归分析校正性别、年龄、国际预后指数评分和R-CHOP周期数后,总生存仍无差异。
关键数值与推荐
- 3年总生存率:原研药组73%,生物类似药组73%,P=.855。
- 接受>6周期R-CHOP比例:生物类似药组24%,原研药组30%,P=.003。
临床怎么用
- 在DLBCL患者中使用利妥昔单抗生物类似药替代原研药不影响3年总生存,可支持临床选择生物类似药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, the Netherlands was one of the first countries to implement R-biosimilars, given lower costs compared with rituximab originator (R-originator). This study's objective was to investigate whether overall survival (OS) of patients with DLBCL receiving R-biosimilars is similar to patients treated with R-originator. DLBCL patients ≥18 years, diagnosed between 2014 and 2018, who received at least 1 cycle of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were identified in the Netherlands Cancer Registry. Patients were categorized into R-originator or R-biosimilars groups based on data from a central repository of the Dutch medicinal drug market. The primary end point was 3-year OS, defined as the time between diagnosis and all-cause death. By the end of 2018, 91% of purchased rituximab were biosimilars. In total, 4429 patients were identified with 876 in the R-biosimilars group and 3553 in the R-originator group. Patients in the R-biosimilars group less frequently received >6 cycles of R-CHOP compared with patients treated with R-originator (24% vs 30%, P = .003). The 3-year OS did not differ between patients treated with R-originator or R-biosimilars (73% vs 73%, P = .855). This was confirmed with a multivariable Cox regression analysis accounting for sex, age, International Prognostic Index score, and number of R-CHOP cycles. In conclusion, the 3-year OS is similar for patients treated with CHOP in combination with R-originator or R-biosimilars and, therefore, favors the use of R-biosimilars in DLBCL treatment management.
引用
- Brink M, Kahle XU, Vermaat JSP, et al. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv. 2021. PMID: 34338755. doi:10.1182/bloodadvances.2021004295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。